This stock no longer trades (delisted May 20, 2026)

Delisted / no longer publicly traded (per market data provider) Everything below is based on the last available data — treat it as historical, not a live read.

PureTech Health

PRTC

Biotechnology · Healthcare

Also trades as: PRTC.L

Price

$17.38

+0.36 (+2.12%)

Market Cap

$4.23B

Exchange

NASDAQ

Winston Score

Historical score — this stock no longer trades, so the score is frozen at the last available data.

Data as of Aug 23, 2026 · filings through Dec 31, 2025

How the score breaks down

Quality

Weak

Growth

Mixed

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Share count falling — buybacks

−91.6% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 28.7M (2021) → 2.4M (2025)

Winston Score History

The full picture

PureTech Health is a biotech company based in the United Kingdom that creates and develops new medicines. It focuses on diseases connected to the brain, immune system, and digestive system — areas where these systems interact in complex ways. PureTech either builds its own drug programs internally or spins them out into separate companies, which it calls "Founded Entities."

The company makes money primarily through milestone payments, royalties, and proceeds from its subsidiary companies rather than selling a single approved drug itself. It operates mainly in the US and UK, with a portfolio of both wholly owned programs and stakes in publicly traded spinouts like Karuna Therapeutics and Gelesis. The deeply negative margins reflect heavy research spending with limited product revenue, which is typical for early-stage biotech. The key risk is that drug development is expensive and uncertain — if pipeline programs fail in clinical trials, the company's value could drop sharply.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-30.5% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-868.6% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$46M/ year

↓ Declining (-16% vs prior year)

981.8% of revenue

54.5x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

35.4%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~3 years

$496M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

$496M cash & investments at current burn rate

Revenue declining

PureTech Health's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

41.0%

Healthy — 41.0% gross margin

Profit after running costs

Operating Margin

-1801.7%

Losing money on operations — -1801.7%

Return on the money invested

ROCE

-31.0%

Weak — -31.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+7.7%

Steady sales growth (+7.7% YoY)

Profit growth

EPS YoY

<−1,000%

Earnings shrinking (<−1,000% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-1824.6%

Burning cash (-1824.6%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.02

Conservative — low debt load (0.02)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial